CTI BioPharma Corp (fka CTIC)

[califax]

... -

http://ih.advfn.com/p.php?pid=nmona&cb=1235291876&article=36358711&symbol=N

"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone..."

...with Exercises Its Option to Sell Interest in Zevalin Joint Venture CTIC will not profit from Zevalin and that date 04/02/09 became unfortunately uninteresting therefore!

?? this is correctly understood ??

*****************************************************************

About Pixantrone

CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non- Hodgkin's lymphoma ( NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.

The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004, and pixantrone has received fast track designation for this indication.

http://ih.advfn.com/p.php?pid=nmona&cb=1235293199&article=36307339&symbol=N^CTIC